Therefore, targeting the NLRP3 inflammasome and the associated receptors could be a novel pharmacological strategy for development of TCM-like, anti-AD drugs, since its inhibition would selectively reduce AD chronic neural inflammation. Here, NLRP3 is linked to Alzheimer disease.